IGM Biosciences
IGM Biosciences, a US-based clinical-stage biotech firm, specializes in creating and enhancing IgM antibodies for improved therapeutic applications.
Founded
2010IGM Biosciences, a US-based clinical-stage biotech firm, specializes in creating and enhancing IgM antibodies for improved therapeutic applications.
IGM Biosciences, founded in Mountain View, United States, is a clinical-stage biotechnology company focused on developing engineered IgM antibodies. Their core mission is to pioneer a new class of antibody medicines aimed at treating cancer, autoimmune, and inflammatory diseases. Leveraging the greater binding power of IgM antibodies compared to the more commonly used IgG antibodies, IGM Biosciences aims to create "super antibodies" that offer improved efficacy and safety in therapeutic applications.
Notable affiliated individuals include the company's leadership team and scientific advisors with extensive experience in biotechnology and immunotherapy. IGM Biosciences has attracted significant investment and partnerships, reflecting confidence in their innovative approach. Key achievements include advancing multiple candidates into clinical trials, demonstrating promising preclinical results, and securing a Nasdaq listing (IGMS). Their work has the potential to significantly impact the treatment landscape for serious diseases, offering new hope to patients worldwide.
Companies similar to IGM Biosciences include IGC BIO, Igenica, iBio and IgGenix.
IGM Biosciences was founded in 2010.
IGM Biosciences' headquarters is located in Mountain View, CA, US.
IGM Biosciences' most recent funding round was for $107.3M (USD) in June 2023.
As of Jun 22, 2023, IGM Biosciences has disclosed funding of $699.3M (USD). Undisclosed round amounts are excluded.
IGM Biosciences has 258 employees as of Feb 6, 2024.
iggenix.com
